Why Achillion Pharmaceuticals Shares Soared in October

By Todd Campbell – Nov 7, 2015 at 9:03AM

NYSE: JNJ

Johnson & Johnson

Market Cap

$356B

Today's Change

(-2.09%) -$3.08

Current Price

$144.51

Price as of April 16, 2024, 1:47 p.m. ET

An upcoming trial by Johnson & Johnson that includes a key drug from this tiny drugmaker could eventually reward investors.

Johnson & Johnson's (JNJ -2.09%) decision to launch a mid-stage study evaluating a slate of hepatitis C drugs that includes Achillion Pharmaceuticals' (ACHN) ACH-3102 could lead to a best-in-class hepatitis C therapy down the road.

In the following slideshow, I outline what you need to know about this trial and why it matters to Achillion Pharmaceuticals' investors.

This iSecret stock could make today's pop look tiny

The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.

Why Achillion Pharmaceuticals Shares Soared in October from The Motley Fool

Todd Campbell owns shares of ACHILLION PHARMACEUTICALS, INC. and Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.